Skip to main content

Table 3 Scheduled visits and assessments

From: Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial

Procedures

Study Visits

SV

C1w0

C1w1

C1w2

C1w4

C2w2

C2w4

C3w2

C3w4

C4w2

C4w4

FV

Informed consent obtained

×

           

Inclusion/exclusion criteria assessments

×

           

History taking

×

           

Physical examination

×

×

×

×

×

×

×

×

×

×

×

×

ECOG status

×

           

Electrocardiogram

×

           

Lab test for complete blood count

×

  

×

×

×

×

×

×

×

×

×

Lab test for fasting blood glucose

×

           

Other lab tests(a)

×

  

×

×

 

×

 

×

 

×

×

Circulating tumor cells

 

×(b)

×(b)

×

 

×

 

×

 

×

  

Biobank collection

×

   

×

 

×

 

×

 

×

×

Urine analysis(c)

×

  

×

×

 

×

 

×

 

×

×

Stool examination

×

          

×

Pharmacokinetic study(d), (e)

 

×

×

         

Pain score & Quality of life

 

×

  

×

 

×

 

×

 

×

×

Review of concomitant medications

×

×

×

×

×

×

×

×

×

×

×

×

Monitoring for adverse events

  

×

×

×

×

×

×

×

×

×

×

Tumor assessment(f)

×

     

×

   

×

 
  1. SV = screening visit; Cxwy = cycle x week y; FV = final visit. (a) Lab tests include Na, K, Cl, HCO3, Ca, Mg, P, albumin, AST, ALT, ALP, total bilirubin, direct bilirubin, BUN, Cr, PT, PTT, INR, and LDH; (b) Blood obtained from the pharmacokinetic study will be used for measurement of circulating tumor cells on C1W0 and C1W1 so that no additional blood samples will be collected; (c) Urine analysis includes a urine pregnancy test for a female patient of childbearing age; (d) Blood samplings (at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 h); (e) Additional samplings for drug monitoring may be required when drug dosage is modified (after ≥7 days of drug administration with an adjusted dose level); (f) Tumor assessment by a computerized tomography (CT) scan (of the chest ± other organs, if required) or magnetic resonance imaging (MRI), done at baseline, 8 ± 1 weeks and 16 ± 1 weeks after initiation of study drug administration; in case of objective tumor response (complete response or partial response), confirmatory imaging studies will be performed at least 4 weeks after initial documentation of response